Table 1 Baseline characteristics of enrolled patients

Patients enrolled, n

101

70

31

Male gender, n (%)

57 (56.44%)

37 (52.86%)

20 (64.51%)

Age (years)

39.93 ± 9.18

40.34 ± 10.05

39.00 ± 6.84

HBV DNA undetectable (< 50 IU/ml), n (%)

89 (89.11%)

52 (74.29%)

27 (87.10%)

HBV DNA detectable (> 50 IU/ml), n (%)

22 (20.79%)

18 (15.71%)

4 (12.90%)

HBsAg (IU/ml)

47.13 (4.88, 218.9)

57.04 (8.92, 256.7)

18.15 (2.29, 147.7)

   HBsAg < 10 IU/ml, n (%)

33 (32.67%)

19 (27.14%)

14 (45.16%)

   HBsAg 10 ~ 100 IU/ml, n (%)

32 (31.68%)

24 (34.29%)

8 (25.81%)

   HBsAg 100 ~ 1000IU/ml, n (%)

29 (28.72%)

22 (31.43%)

7 (22.58%)

   HBsAg > 1000 IU/ml, n (%)

7 (6.93%)

5 (7.14%)

2 (6.45%)

HBeAg positive, n (%)

5 (4.95%)

5 (7.14%)

0 (0.00%)

PEG-IFN-α-2b monotherapy, n (%)

31 (30.69%)

0

31

PEG-IFN-α-2b add-on NAs therapy, n (%)

70 (69.31%)

70

0

   ETV, n (%)

42 (60.00%)

42

0

   TDF, n (%)

17 (24.29%)

17

0

   TAF, n (%)

6 (8.57%)

6

0

   TMF, n (%)

5 (7.14%)

5

0

Blood routine test

   White blood cells (×10⁹/L)

5.29 ± 1.39

5.03 ± 1.15

5.88 ± 1.71

   Neutrophils (×10⁹/L)

3.14 ± 1.01

2.99 ± 0.81

3.49 ± 1.30

   Platelets (×10⁹/L)

205.3 ± 57.60

201.0 ± 60.14

214.9 ± 51.00

   Red blood cells (×10¹²/L)

4.91 ± 0.55

4.87 ± 0.59

5.01 ± 0.44

   Hemoglobin (g/L)

148.7 ± 19.45

147.8 ± 19.28

150.7 ± 19.99

Liver function

   ALT (U/L)

23.00 (16.00, 30.75)

23.00 (16.00, 31.00)

21.50 (14.75, 28.25)

   AST (U/L)

21.50 (18.00, 26.00)

22.00 (18.75, 26.00)

20.00 (18.00, 23.75)

   T-BIL (µmol/L)

17.75 (10.60, 21.30)

17.00 (11.10, 22.23)

11.55 (9.35, 17.03)

   Total protein (g/L)

73.46 ± 8.15

73.00 ± 9.10

74.60 ± 4.99

   Albumin (g/L)

48.83 ± 3.38

48.94 ± 3.30

48.55 ± 3.60

   Globulin (g/L)

25.41 ± 3.26

25.02 ± 3.43

26.27 ± 2.61